BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 02, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Intuvax: Phase I/II data

Data from 2 patients with poor prognosis in a Swedish Phase I/II trial showed that Intuvax led to an average survival of about 14 months. Immunicum said the expected median survival is 5 months in untreated patients and 8 months patients treated with existing therapies such as...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >